If you’ve listened to more than one of our podcasts, you’ll probably be aware of the problem of the opacity of clinical trial data - trials which are conducted by never see the light of day, or results within those trials which are never published.
Pharmaceutical companies have their own policies on what they are willing to make public, when, and for the first time a new audit, published on bmj.com, collates and analyses those policies.
To discuss that study I’m joined by two of the authors - Ben Goldacre, senior clinical research fellow at, and Carl Heneghan, director of, Oxford's Centre for Evidence Based Medicine.
Read the full audit:
http://www.bmj.com/content/358/bmj.j3334
